Lakefront Biotherapeutics (LKFT) Operating Leases (2019 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Operating Leases for 8 consecutive years, with $5.5 million the latest figure, recorded in Q1 2026.

• Quarterly Operating Leases fell 37.7% year-over-year to $5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 million (down 37.7% YoY) and the FY2025 annual result came in at $5.9 million, down 55.76% from the prior year.
• Operating Leases fell to $5.5 million in Q1 2026 per LKFT's latest filing, from $5.9 million in the prior quarter.
• Over the last five years, Operating Leases for LKFT reached as high as $20.8 million in Q1 2022 and fell as low as $4.4 million in Q1 2024.
• A 5-year average of $10.0 million and a median of $8.9 million in 2025 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2024 — Operating Leases slumped 62.44% — and 2025, when it soared 102.95%.
• Year by year, Operating Leases stood at $16.7 million in 2022, then sank by 34.69% to $10.9 million in 2023, then grew by 22.16% to $13.3 million in 2024, then slumped by 55.76% to $5.9 million in 2025, then declined by 6.46% to $5.5 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $5.5 million, $5.9 million, and $6.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.